Traws Pharma (TRAW) investor relations material

Executive summary

• No revenue recognized in Q2 2026; prior year revenue was $2.7M, following termination of a key license agreement in April 2025.

• Net loss of $3.0M for Q2 2026, compared to $0.9M net loss in Q2 2025; six-month net loss of $10.2M vs. net income of $20.6M in 2025, which included a $26.7M non-cash gain from warrant liabilities.

• Advanced tivoxavir marboxil toward MHRA resubmission in Q3 2026 with a revised toxicology package, supporting a planned Phase 2a human influenza Challenge study.

• Completed April 2026 private placement, securing $10M upfront and potential access to $50M in milestone-based financing, subject to program achievements and investor participation.

• Platform expanded to early-stage leads for other viral threats, including hantavirus, Ebola, and Lassa fever.

Financial highlights

• Cash and cash equivalents at June 30, 2026: $5.0M; accumulated deficit: $650.1M.

• R&D expenses for Q2 2026: $1.1M (down 52% YoY); G&A expenses: $3.5M (up 106% YoY).

• Six-month R&D expenses: $6.0M (up 25% YoY); G&A: $5.5M (up 24% YoY).

• Other operating income of $1.4M in Q2 2026 from removal of a legacy R&D obligation.

• Total assets: $11.5M; total liabilities: $9.8M as of June 30, 2026.

Outlook and guidance

• MHRA resubmission for tivoxavir marboxil expected by end of Q3 2026; Phase 2a Challenge study to follow pending approval.

• FDA clinical hold on U.S. IND for TXM being addressed, with a goal to resolve by end of 2026.

• Current cash and anticipated proceeds expected to fund operations into Q1 2027; additional financing may be required thereafter.

• Exploring additional financing options, including equity, partnerships, and warrant exercises.

• Expect higher net cash expenditures in 2026 due to clinical trials and increased headcount.